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Abstract Systemic infections due to Mycoplasma hom-
inis are rare and occur mainly in immunocompromised
patients. Reported here are the cases of two renal
transplant patients with peritonitis who did not respond
to empirical antimicrobial treatment. Effective treatment
with doxycycline was administered only after definitive
identification of Mycoplasma hominis was achieved. For
this identification, the new genetic amplification-sequenc-
ing method was invaluable.
Introduction
Mycoplasma hominis is known to colonize the urogenital
tract and may cause localized infections, but it rarely
causes severe infections [1, 2, 3]. Among the few cases of
systemic infection that have been reported previously, the
affected patients were mostly immunocompromised and
had undergone renal transplantation [2, 4, 5]. Reported
here are two additional cases of systemic Mycoplasma
hominis infections that occurred following renal trans-
plantation.
Case Reports
Case 1 involved a 33-year-old female who had been diagnosed with
diabetes mellitus type I in 1975 and had severe hypertension with
cardiac complications. Since 1999 she had been receiving hemo-
dialysis treatment for terminal renal insufficiency, and in 2001 she
underwent renal and pancreatic allograft transplantation. On day 10
after surgery, the patient presented with fever, diarrhea and
abdominal fluid collection in the pouch of Douglas. Drainage
was performed, and Enterococcus faecium was isolated from a
hematoma. Empiric antimicrobial therapy was begun with amox-
icillin and gentamicin, but this was replaced by vancomycin and
gentamicin when susceptibility testing of the isolate revealed
amoxicillin resistance. On postoperative day 27, the nephrotoxic
vancomycin and gentamicin combination was replaced by linezol-
id.
On day 36 a computed tomography-guided aspirate was col-
lected. Although no microorganisms could be visualized micro-
scopically on Gram stain, many leukocytes were present and, after
2 days of incubation on Columbia blood agar, hemolytic, translu-
cent colonies grew abundantly (i.e., on all streaked quadrants).
Gram stain of these colonies was also negative, whereupon myco-
plasma infection was suspected. Amplification and sequencing of
the 16S ribosomal RNA gene from these colonies definitively
identified Mycoplasma hominis [6]. Based on this result, antimi-
crobial treatment was changed to doxycycline. In parallel, a urinary
tract infection due to Escherichia coli and Klebsiella oxytoca was
diagnosed, and ciprofloxacin was added with a favorable outcome.
Case 2 involved a 56-year-old diabetic female with a history of
end-stage renal failure who had received a renal graft in 1986 as
well as pancreatic cell injection in 1997. Unfortunately, both organs
were non-functional. In 2002 she was readmitted for double
transplantation of the kidney and pancreatic islets. The patient’s
clinical evolution was favorable from the aspect of transplantation,
but she experienced several subfebrile peaks (38 to 38.5C) and a
urinary tract infection was suspected to be the cause.
Microbial urine cultures yielded mixed gram-positive flora
(104 cfu/ml). Antibiotic therapy with ceftriaxone was initiated, but
the patient’s abdominal status did not improve. An abdominal
computed tomography scan was subsequently performed, revealing
an infrarenal fluid collection of about 5 cm in diameter; a sample
was collected by aspiration on postoperative day 18 and submitted
for microbiological analysis. Antibiotic therapy was then switched
to imipenem, since a mixed infection with anaerobic bacteria was
suspected. As in the preceding case, no microorganisms could be
visualized microscopically, but abundant leukocytes and many
hemolytic translucent colonies appeared on blood agar plates after
2 days of incubation. Again, infection with a Mycoplasma sp. was
suspected and subsequently confirmed when Mycoplasma hominis
was identified by amplification and sequencing. Accordingly,
antimicrobial treatment was changed to doxycycline on day 23, and
the patient improved remarkably; in fact, she was able to leave the
hospital 30 days after surgery.
Discussion
Mycoplasma spp. are small bacteria (0.2–0.3 m in
diameter) that lack a typical bacterial peptidoglycan cell
wall; therefore, they cannot be visualized on Gram stain.
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For the same reason, they present a pleomorphic mor-
phology (round to filamentous) and are not susceptible to
antibiotics that inhibit peptidoglycan synthesis, like peni-
cillins, cephalosporins, carbapenems, or glycopeptides
[1]. Furthermore, mycoplasmas are difficult to detect by
culture due to their fastidious growth requirements, which
are associated with their extremely small genomes and
their limited biosynthetic capabilities.
The origin of Mycoplasma hominis infections in
transplant patients may be the colonized urogenital tract
of either the recipient or the donor of the graft. Renal
transplant patients are therefore particularly at risk after
surgical interventions of the urogenital tract and due to
their immunosuppression. However, extragenital Myco-
plasma hominis infections have also been reported in
heart, heart and lung, or liver transplant patients [2] who
have not undergone surgical manipulation of the urogen-
ital tract. In these patients, immunosuppression is cer-
tainly the main risk factor.
Although Mycoplasma hominis is an organism of low
pathogenicity, it can lead to a fatal outcome if adequate
treatment is not administered [2]. For this reason, it is
important to detect these infections reliably and rapidly.
Many cases may not be diagnosed owing to the difficulty
of staining, growing and identifying this organism using
traditional microbiological techniques. Microbiologists
should be aware that Mycoplasma hominis grows on
common media such as blood agar-based media, on which
colonies can often be recognized by their hemolysis [3].
Gram stain of these colonies reveals no common bacteria,
subcultures rarely grow, and conventional microbiologi-
cal procedures can only identify the microorganism with
the help of unusual and complicated techniques [4]. Thus,
a much more reliable and rapid identification method is
the now more commonly applied genetic amplification of
the eubacterial 16S ribosomal RNA gene by PCR, using
broad-range primers [6]. The subsequent sequencing of
the PCR product allows a definitive identification, not
only of mycoplasmas but of many other bacteria as well
[6, 7]. Nevertheless, the diagnosis may be complicated
when mixed infections with other more common bacteria
occur, as illustrated in case 1 reported above.
Treatment of Mycoplasma hominis infections with
certain widely used antimicrobial agents is ineffective,
owing to the inherent resistance of Mycoplasma spp. to
agents acting on peptidoglycan synthesis (e.g., beta-
lactam antibiotics, glycopeptides). Susceptibility tests
may be performed with commercial kits, such as Myco-
plasma IST (bioMrieux, Lyon, France), however it is
difficult to achieve standardized inocula and consistent
result interpretation [1]. Empirically, tetracyclines and
quinolones are the drugs of choice for treating these
infections [2, 4, 5].
The two cases reported here emphasize the importance
of rapid, definitive diagnosis in order to achieve optimal
patient outcome. However, since many cases may remain
undiagnosed, the real incidence and outcome of these
infections without specific treatment remains unknown. In
the cases reported here, the new and more readily
available molecular biological methods proved invaluable
in achieving an accurate diagnosis.
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